Medpace (NASDAQ:MEDP) Issues FY 2025 Earnings Guidance

Medpace (NASDAQ:MEDP) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 12.260-13.040 for the period, compared to the consensus estimate of 12.480. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Truist Financial dropped their price objective on shares of Medpace from $347.00 to $333.00 and set a “hold” rating on the stock in a research note on Thursday, April 10th. TD Cowen downgraded Medpace from a “buy” rating to a “hold” rating and lowered their target price for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price target for the company. Finally, Mizuho reduced their target price on Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a report on Wednesday, April 9th. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $357.50.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $288.99 on Tuesday. The firm has a market cap of $8.74 billion, a P/E ratio of 22.88, a PEG ratio of 3.81 and a beta of 1.46. The stock has a fifty day moving average price of $317.57 and a two-hundred day moving average price of $332.88. Medpace has a 1 year low of $269.08 and a 1 year high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period last year, the company posted $3.20 EPS. On average, research analysts predict that Medpace will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.